LGM Pharma is a proven CDMO partner specializing in solid dose delivery systems, producing more than 275 million solid doses annually. With a history of pharmaceutical manufacturing excellence dating back to the 1940s, LGM Pharma provides complete end-to-end services—from formulation and R&D through commercial-scale production—across tablets, capsules, beads, powders, and granules.
At the core of LGM Pharma’s capabilities is its ability to customize delivery mechanisms such as immediate, sustained, controlled, and extended-release formulations. The company utilizes advanced manufacturing processes including high- and low-shear wet granulation, spray granulation, bead layering, coating, and encapsulation to produce both generic and innovator formulations, including controlled substances (DEA Class II–V). Batch flexibility allows for production ranging from small clinical runs to commercial quantities exceeding two million units, ensuring scalability from pilot to market.
Beyond manufacturing excellence, LGM Pharma integrates Quality by Design (QbD) principles throughout its process development and manufacturing lifecycle. All products are made in FDA-inspected, cGMP-certified facilities in Colorado Springs and Irvine, CA, equipped with full serialization, track-and-trace, and in-house analytical testing capabilities. By embedding quality and reproducibility into every stage—from sourcing APIs to packaging finished products—LGM Pharma ensures consistency, safety, and regulatory compliance across every solid dose project.
Key Highlights:
- Manufactures 275 million+ solid doses annually with proven scalability.
- Expertise in immediate, sustained, controlled, and extended-release systems.
- Capabilities include wet/dry granulation, bead coating, and encapsulation.
- FDA-inspected, cGMP facilities with integrated analytical testing and serialization.
